Strategic collaboration formed to raise awareness that all people with diabetes on blood glucose-lowering medications should have glucagon, preferable a ready-to-use formulation CHICAGO and ARLINGTON, Va., Jan. 21, 2025 /PRNewswire/ -- The American Diabetes Association® (ADA) and Xeris Pharmaceuticals® (Xeris BioPharma Holdings, Inc.), a national supporter of the ADA, are pleased to announce a multi-year strategic partnership to reinforce the importance of prescribing glucagon, preferably ready-to-use, for ...

Financial Results Announcement - Xeris Biopharma Holdings, Inc. announced preliminary financial results for Q4 and full year ended December 31, 2024 [7] - The press release detailing the financial results is attached as Exhibit 99.1 to the Form 8-K [7] Company Information - The company's common stock is traded on the Nasdaq Global Select Market under the symbol XERS [2] - The company is incorporated in Delaware and has its principal executive offices in Chicago, Illinois [4] Report Filing Details - The report was filed on January 10, 2025, and signed by Steven M. Pieper, the Chief Financial Officer [3]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission file number: 001-40880 XERIS BIOPHARMA HOLDINGS, INC. (Exact name of the registrant as specified in its charter) Delaware 87 ...

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q3 2024 Earnings Conference Call November 8, 2024 8:30 AM ET Company Participants John Shannon - Chief Executive Officer Steve Pieper - Chief Financial Officer Allison Wey - Senior Vice President of Investor Relations, Corporate Communications Conference Call Participants Chase Knickerbocker - Craig-Hallam Leland Gershell - Oppenheimer. Oren Livnat - HC Wainwright Nik Gasic - Leerink Partners David Amsellem - Piper Sandler Operator Hello and welcome to the Xer ...

Xeris Biopharma (XERS) reported $54.27 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 12.3%. EPS of -$0.06 for the same period compares to -$0.09 a year ago.The reported revenue represents a surprise of +5.09% over the Zacks Consensus Estimate of $51.64 million. With the consensus EPS estimate being -$0.09, the EPS surprise was +33.33%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare t ...

Xeris Biopharma (XERS) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.09 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 33.33%. A quarter ago, it was expected that this company would post a loss of $0.11 per share when it actually produced a loss of $0.10, delivering a surprise of 9.09%.Over the last four quarters, the company has surpassed ...

Exhibit 99.1 XERIS BIOPHARMA REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS Achieved record total revenue of $54.3M including record product revenue of $52.9M Product revenue increased 27% versus prior year and 14% over the prior quarter Ended Q3 with $69.4M in cash, cash equivalents and short-term investments Raises full-year guidance of total net revenue to $198M-$202M and tightens year-end cash to $68M-$72M Hosting conference call and webcast today at 8:30 a.m. ET CHICAGO, IL; November 8, 2024 – Xeris Biop ...

Editor's note: Seeking Alpha is proud to welcome PJ Research as a new contributing analyst. You can become one too! Share your best investment idea by submitting your article for review to our editors. Get published, earn money, and unlock exclusive SA Premium access. I'm an Investment Officer specializing in private equity and venture capital, focused on cutting-edge sectors like deeptech, quantum technologies, biotechnology, pharmaceuticals, and the energy transition. My approach is to evaluate the addres ...

Join Compounding Healthcare where we employ data analytics in combination with technical analysis and clinical data breakdown in order to manage a position in numerous potential multi-bagger investments that can grow into a comprehensive healthcare portfolio. It has been roughly seven months since my last Xeris Biopharma Holdings, Inc. (NASDAQ: XERS ) article , where I revealed that I was adopting a conservative stance while waiting on a strong reversal setup combined He is the leader of the investing group ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission file number: 001-40880 XERIS BIOPHARMA HOLDINGS, INC. (Exact name of the registrant as specified in its charter ...